Zura Bio ZURA 深 沪
等待开盘 09-15 09:30:00 美东时间
5.21
0.000
0.00%
华盛通- 最 高5.36
- 今 开5.21
- 成交量 104.54万股
- 最 低 5.15
- 昨 收 5.21
- 总市值 4.99亿
- 52周最高 7.44
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 2.00
- 委 比 95.70%
- 总股本 9582.91万
- 历史最高 37.55
- 量 比 0.71
- 振 幅 4.03%
- 历史最低 0.97
- 每 手 1
- 风险率 1.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20
Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.
08-12 20:28
William Blair Initiates Coverage On Zura Bio with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Zura Bio (NASDAQ:ZURA) with a Outperform rating.
07-09 02:54
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy
On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy across severe autoimmune diseases. Analyst Matt Phipps said the investment thesis centers on tibuliz...
07-09 01:24
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target
Wedbush analyst Martin Fan reiterates Zura Bio (NASDAQ:ZURA) with a Outperform and maintains $15 price target.
07-01 21:56
Zura Bio大涨44% 大额资金离场
祖拉生物（ZURA.O）近期股价累计上涨44.59%，当前处于高波动状态，机构与散户资金流向呈现明显分化。 核心关键数据： 基本面：资产市值比为-21.66...
06-30 10:18
Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS
Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE has exceeded the 80 participant enrollment targe...
06-29 19:32
Zura Bio：分析师给出买入评级 聪明资金却在抛售
祖拉生物（ZURA.O）当前呈现多空博弈格局，生物科技板块整体受大额资本布局支撑，但个股自身技术面方向不明，波动将持续，暂无单边上涨基础。 核心行业动态：B...
06-29 10:18
